Medical Access in Taiwan

Currently classified as a strictly controlled substance under Taiwan's controlled‑drugs/narcotics framework, with no authorized medical use outside of approved clinical research. Public materials from Taiwan's Ministry of Health and Welfare and associated TFDA communications list psilocybin and related 'psychedelic' or 'novel psychoactive' compounds among substances targeted for criminal control and public‑health warnings; there is no publicly available TFDA marketing authorization or routine reimbursement pathway for psilocybin medicines in Taiwan as of Feb 20, 2026. [1]MOHW: New Psychoactive Substances advisory [2]BlossomAnalysis country summary.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Taiwan's public health and law‑enforcement communications explicitly treat MDMA and related amphetamine‑type/phenethylamine substances as illicit and part of the 'club drug'/new psychoactive threats; no public reimbursement program or routine medical prescription pathway exists for MDMA in Taiwan. [1]MOHW: New Psychoactive Substances advisory [2]MOHW narcotics education page.

As of Feb 20, 2026 there is no clear, publicly indexed TFDA (Taiwan Food and Drug Administration / Ministry of Health and Welfare) marketing authorization record for Janssen's esketamine (Spravato®) in Taiwan available on TFDA/MOHW public channels; esketamine therefore should not be assumed to have an established reimbursed pathway in Taiwan. Locally, ketamine (racemate) is a recognized medical anaesthetic and appears in Taiwan clinical practice and regulatory discussions, and Taiwanese industry/academic groups have been involved in clinical development of ketamine‑based products externally, but a TFDA approval and National Health Insurance (NHI) reimbursement listing for an esketamine branded nasal spray have not been publicly documented in TFDA/MOHW materials accessible as of Feb 20, 2026. Clinicians seeking to use esketamine would therefore be limited to formally approved clinical trials or an imported/compassionate‑use pathway subject to TFDA approval; routine prescription and NHI reimbursement are not evidenced. [1]MOHW: drug approval & safety information portal [2]MOHW: new psychoactive/control notices.

Ketamine is a legally recognized medical anesthetic and is used in Taiwanese clinical settings under standard medical regulation, but it is a controlled substance and non‑medical possession, diversion or trafficking are criminal offenses. Taiwanese public health communications and legal summaries classify ketamine among substances subject to scheduling and active law‑enforcement monitoring; clinical use (e.g., as an anesthetic) occurs within regulated hospitals and clinics, but use for psychiatric indications is largely delivered off‑label (clinic‑level protocols) rather than via an NHI‑reimbursed, labeled psychedelic medicine program. There is active industry and research interest from Taiwanese companies in ketamine formulations and clinical trials (examples of local companies pursuing ketamine‑based products abroad), but routine national reimbursement for ketamine when used as a psychiatric intervention is not an established, codified NHI benefit—such uses are typically arranged via private clinic billing or research protocols. For regulatory context and public advisories about ketamine as a controlled/club drug and medical agent see Taiwan MOHW materials. [1]MOHW: New psychoactive substances advisory [2]MOHW narcotics/ATS advisories.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT (and synthetic tryptamines) are treated as illicit by Taiwan authorities; there is no established clinical prescribing framework or NHI reimbursement for DMT products. [1]MOHW: New psychoactive substances advisory.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Taiwan's controlled‑substances enforcement and public‑health messaging include synthetic tryptamines and novel psychoactive tryptamine derivatives among illicit targets; no medical authorization or reimbursement pathway exists for 5‑MeO‑DMT. [1]MOHW advisory.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no authorized ibogaine treatment program or reimbursement mechanism in Taiwan; possession, importation or distribution would fall under narcotics/controlled‑drugs penalties unless part of a TFDA‑approved research protocol. [1]MOHW: controlled substances guidance.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Preparations that contain DMT (such as ayahuasca) are treated under the same controlled‑substances framework as DMT; there is no medical authorization or public reimbursement for ayahuasca in Taiwan. [1]MOHW advisory.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (and mescaline‑containing cacti preparations) are controlled; no clinical/reimbursed medical program exists for mescaline in Taiwan. [1]MOHW advisory.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Taiwan's public materials specifically list a broad set of substituted phenethylamines/new phenethylamine‑type NPS (including 2C‑series members) as part of controlled/illicit substances; there is no authorized medical access or reimbursement for 2C‑X compounds. [1]MOHW: New psychoactive substances advisory [2]MOHW narcotics info.